Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
35964471
DOI
10.1016/j.ejca.2022.06.041
PII: S0959-8049(22)00392-6
Knihovny.cz E-resources
- Keywords
- AJCC-8 criteria, Distant metastases, Ipilimumab, Melanoma adjuvant therapy, Nivolumab, Recurrence-free survival, Stage 3,
- MeSH
- Adjuvants, Immunologic adverse effects MeSH
- Ipilimumab adverse effects MeSH
- Humans MeSH
- Melanoma, Cutaneous Malignant MeSH
- Melanoma * drug therapy surgery MeSH
- Skin Neoplasms * drug therapy surgery MeSH
- Nivolumab adverse effects MeSH
- Neoplasm Staging MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Ipilimumab MeSH
- Nivolumab MeSH
PURPOSE: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8. PATIENTS AND METHODS: In a double-blind, phase 3 trial (NCT02388906), patients aged ≥15 years with resected, histologically confirmed AJCC-7 stage IIIB, IIIC, or IV melanoma were randomised to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, both intravenously ≤1 year. Recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were assessed in patients with stage III disease, per AJCC-7 and AJCC-8. RESULTS: Per AJCC-7 staging, 42.4% and 57.3% of patients were in substage IIIB and IIIC, respectively; per AJCC-8, 1.1%, 30.4%, 62.8%, and 5.0% were in IIIA, IIIB, IIIC, and IIID. After 4 years' minimum follow-up, the AJCC-7 superior efficacy of nivolumab over ipilimumab in patients with resected stage III melanoma was preserved per AJCC-8 analysis. No statistically significant difference in RFS between stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria (interaction test: AJCC-7, P = 0.8115; AJCC-8, P = 0.1051; P = 0.8392 ((AJCC-7) and P = 0.8678 (AJCC-8) for DMFS). CONCLUSIONS: CheckMate 238 4-year RFS and DMFS outcomes are consistent per AJCC-7 and AJCC-8 staging criteria. Outcome benefits can therefore be translated for patients diagnosed per AJCC-8.
Center for Immuno Oncology University Hospital of Siena Siena Italy
Department of Clinical Oncology Hospital University Virgen Macarena Seville Spain
Department of Cutaneous Oncology H Lee Moffitt Cancer Center Tampa FL USA
Department of Dermatology Aix Marseille University Hôpital de La Timone Marseille France
Department of Dermatology Hospices Civils de Lyon Pierre Bénite France
Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece
Department of Internal Medicine University of Michigan Rogel Cancer Center Ann Arbor MI USA
Department of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto ON Canada
Department of Medical Oncology Hospital Clínic de Barcelona IDIBAPS Barcelona Spain
Department of Medical Oncology Oncology Center Sf Nectarie Craiova Romania
Department of Medical Oncology Tasman Health Care Southport QLD Australia
Department of Medical Oncology Texas Oncology Baylor Charles A Sammons Cancer Center Dallas TX USA
Department of Medical Oncology The Royal Marsden NHS Foundation Trust London UK
Department of Oncology Churchill Hospital Oxford UK
Melanoma Oncology Unit Veneto Institute of Oncology IOV IRCCS Padua Italy
Oncology Clinical Development Bristol Myers Squibb Princeton NJ USA
References provided by Crossref.org
ClinicalTrials.gov
NCT02388906
